Hjem › Myelofibrose › Illinois
Myelofibrose kliniske forsøg i Illinois
7 studier for Myelofibrose søger deltagere på steder i Illinois.
Byer i Illinois
Officiel studietekst (engelsk)
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- University of Chicago, Chicago
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT04176198A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
- University of Chicago Comprehensive Cancer Center, Chicago
- UC Comprehensive Cancer Center at Silver Cross, New Lenox
- University of Chicago Medicine-Orland Park, Orland Park
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT06661915A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
- University of Chicago Medical Center, Chicago
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 6. aug. 2026 · NCT07008118Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- University of Chicago, Chicago
RekruttererFase 1
Alder 13 og opefter · Alle køn · Opdateret 5. maj 2026 · NCT04771572MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
- MPN Research Foundation, Chicago
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 23. jan. 2026 · NCT07362225Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
- The University of Chicago, Chicago
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 29. dec. 2025 · NCT03326310SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chicago
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 28. okt. 2025 · NCT03452774Fra ClinicalTrials.gov, data hentet 4. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.